Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Novo Nordisk ASWBO:NNO2 +0.79%80 Days Sales Outstanding is 99.72 as of Jun. 2026, which is 25% above its 10-year median of 80.01. GuruFocus rates WBO:NNO2 with a GF Score™ of 80/100 and a GF Value™ of €94.89 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 945 Drug Manufacturers companies, Novo Nordisk AS ranks worse than 62.86% on this metric.
Novo Nordisk AS's average Accounts Receivable for the
three
months ended in Jun. 2026 was €11,471 Mil. Novo Nordisk AS's Revenue for the
three
months ended in Jun. 2026 was €10,497 Mil.
Hence, Novo Nordisk AS's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 99.72.
The historical rank and industry rank for Novo Nordisk AS's Days Sales Outstanding or its related term are showing as below:
WBO:NNO2'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 58.32 Med: 80.01 Max: 94.06
Current: 85.84
During the past 13 years, Novo Nordisk AS's highest Days Sales Outstanding was 94.06. The lowest was 58.32. And the median was 80.01.
WBO:NNO2's Days Sales Outstanding is ranked worse than 62.86% of 945
companies
in the Drug Manufacturers industry
Industry Median: 71.8
vs WBO:NNO2: 85.84
Novo Nordisk AS's Days Sales Outstanding
increased
from Jun. 2025 (82.54) to Jun. 2026 (99.72).
Novo Nordisk AS (WBO:NNO2) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Novo Nordisk AS Days Sales Outstanding Related Terms
Novo Nordisk AS Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Novo Nordisk AS's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:NNO2 vs LLY, JNJ, ABBV: Days Sales Outstanding Comparison
For the Drug Manufacturers - General subindustry, Novo Nordisk AS's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novo Nordisk AS Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Novo Nordisk AS's Days Sales Outstanding falls into.
Novo Nordisk AS Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novo Nordisk AS (WBO:NNO2) has a Days Sales Outstanding of 99.72 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Novo Nordisk AS and its competitors. This is 25% above median its historical median of 80.01. Over the past decade, Novo Nordisk AS's Days Sales Outstanding has ranged from 58.32 to 94.06. According to the industry distribution chart, Novo Nordisk AS ranks #594 out of 945 companies in the Drug Manufacturers industry, placing it in the top 62.9%.
Is Novo Nordisk AS's Days Sales Outstanding too high?
Novo Nordisk AS's current Days Sales Outstanding of 99.72 is 25% above median its 10-year median of 80.01. Over the past 10 years, this metric has ranged from a low of 58.32 to a high of 94.06. The Drug Manufacturers industry median Days Sales Outstanding is 71.80. Novo Nordisk AS's value of 99.72 is 38.9% above this industry median. Based on the distribution chart, Novo Nordisk AS ranks #594 out of 945 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Novo Nordisk AS has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's Days Sales Outstanding compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Novo Nordisk AS ranks #594 out of 945 companies for Days Sales Outstanding. This places Novo Nordisk AS in the lower half of its industry. The industry median Days Sales Outstanding is 71.80. Novo Nordisk AS's value of 99.72 is 38.9% above this benchmark. Historically, Novo Nordisk AS's own Days Sales Outstanding has ranged from 58.32 to 94.06 over the past decade. While the company's 10-year median is 80.01 vs. the industry median of 71.80, Novo Nordisk AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 71.80, based on 945 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novo Nordisk AS's current Days Sales Outstanding of 99.72 is 38.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Novo Nordisk AS and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 71.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novo Nordisk AS's current Days Sales Outstanding is 99.72, which is 25% above median its own 10-year median of 80.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (WBO:NNO2) is currently considered Significantly Undervalued. The stock's GF Value™ is €94.89, compared to a current price of €40.08 — trading 57.8% below its estimated fair value. The current Days Sales Outstanding is 99.72, which is 25% above median its 10-year median of 80.01 and 38.9% above the Drug Manufacturers industry median of 71.80. Novo Nordisk AS's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Novo Nordisk AS (WBO:NNO2), the current Days Sales Outstanding is 99.72 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novo Nordisk AS (WBO:NNO2) Overvalued in 2026?
Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued.
The current stock price of €40.08 is trading 57.8% below its estimated GF Value™ of €94.89.
GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.
Key valuation signals for WBO:NNO2:
Days Sales Outstanding: 99.72 (25% above median its 10-year median of 80.01)
GF Value™: €94.89 vs. price of €40.08 (57.8% below fair value)
Industry Position: 38.9% above the Drug Manufacturers median (#594 of 945)
No single metric tells the full story. See the WBO:NNO2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
80GF Score
Get the complete analysis for WBO:NNO2
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:NNO2 has been successfully added to your 
